Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

AIMS: Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after an exacerbation of HF in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zannad, Faiez, Greenberg, Barry, Cleland, John G.F., Gheorghiade, Mihai, van Veldhuisen, Dirk J., Mehra, Mandeep R., Anker, Stefan D., Byra, William M., Fu, Min, Mills, Roger M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Study Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029775/
https://www.ncbi.nlm.nih.gov/pubmed/25919061
http://dx.doi.org/10.1002/ejhf.266

Ejemplares similares

Ejemplares similares